OSLI Retina

May/June 2013

Issue link: http://osliretina.healio.com/i/129075

Contents of this Issue

Navigation

Page 1 of 99

ONE INJECTION, EARLY INTERVENTION. TAKE ACTION WITH JETREA® (ocriplasmin) Intravitreal Injection, 2.5 mg/mL The FIRST and ONLY pharmacologic treatment for symptomatic Vitreomacular Adhesion (VMA).1 Indication JETREA (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion. Important Safety Information Warnings and Precautions • A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately. • Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye. Please see Brief Summary of full Prescribing Information on adjacent page. Reference: 1. JETREA [package insert]. Iselin, NJ: ThromboGenics, Inc.; 2012. ©2013 ThromboGenics, Inc. All rights reserved. ThromboGenics, Inc., 101 Wood Avenue South, Suite 610, Iselin, NJ 08830 – USA. JETREA and the JETREA logo are trademarks or registered trademarks of ThromboGenics NV in the United States, European Union, Japan, and other countries. THROMBOGENICS and the THROMBOGENICS logo are trademarks or registered trademarks of ThromboGenics NV in the United States, European Union, Japan, and other countries.

Articles in this issue

Archives of this issue

view archives of OSLI Retina - May/June 2013